Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Stroke Vasc Neurol

Supplementary Table. Baseline and procedure characteristics of MeVO patients with 90-day good outcome/poor outcome

Baseline and procedure variables	Good outcome (n=66)	Poor outcome (n=81)	P value
Age, y, median（IQR）	67(59-73)	67(60-76)	0.687
Men, n (%)	35(53.0)	40(49.4)	0.660
Hypertension, n (%)	32(48.5)	49(60.5)	0.145
DM, n (%)	10(15.2)	13(16.1)	0.882
Hyperlipidemia, n (%)	2(3.0)	4(4.9)	0.561
Coronary heart disease, n (%)	7(10.6)	13(16.1)	0.338
Atrial fibrillation, n (%)	20(30.3)	39(48.2)	**0.028**
Valvular heart disease, n (%)	2(3.0)	4(4.9)	0.561
Prior stroke, n (%)	13(20.0)	23(28.4)	0.223
Smoking history, n (%)			0.114
Never smoking	42(53.6)	58(71.6)	
Previous smoking	3(4.6)	8(9.9)	
Current smoking	21(31.8)	15(18.5)	
SBP, mmHg	145(132-160)	146(133-160)	0.833
Admission NIHSS	13(10-17)	17(13-20)	**0.001**
ASPECTS§	10(9-10)	9(7-10)	**0.016**
Serum glucose, mmol/L, median（IQR）	6.6(5.8-7.4)	7.0(5.8-8.6)	0.229
Blood WBC, 10^9/L, median（IQR）	7.6(6.8-8.8)	8.2(6.4-11.4)	0.241
NLR, median（IQR）	3.4(2.3-5.7)	4.9(2.6-8.6)	**0.029**
Pretreatment with antiplatelets, n (%)	8(12.1)	16(19.8)	0.213
Pretreatment with IVT, n (%)	46(69.7)	57(70.4)	0.929
Underlying ICAD, n (%)			
Yes	12(18.2)	14(17.3)	0.944
NO	47(71.2)	57(70.4)	
Undetermined	7(10.6)	10(12.4)	
General anesthesia, n (%)	14(21.2)	30(37.0)	**0.037**
Stroke subtype by TOAST criteria			0.498
Large artery atherosclerosis	27(40.9)	28(34.6)	
Cardioembolism	27(40.9)	35(43.2)	
Other or unknown etiology	11(16.7)	13(16.1)	
Undetermined	1(1.52)	5(6.2)	
Stent retriever, n (%)	56(84.9)	77(95.1)	**0.036**
Aspiration, n (%)	5(7.6)	10(12.4)	0.342
IAT, n (%)	14(21.2)	7(8.6)	**0.030**
Balloon angioplasty, n (%)	4(6.1)	5(6.2)	0.978

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Stroke Vasc Neurol

Stenting, n (%)	1(1.5)	4(4.9)	0.255
GP IIb/IIIa receptor inhibitor, n (%)	26(39.4)	27(33.3)	0.447
OTP, min, median（IQR）‖	265(210-405)	292(203-413)	0.791
Number of MT passes, median (IQR)	1(1-2)	2(1-2)	**0.003**
FPR, n (%)	42(64.6)	42(51.9)	0.121
Procedure duration, min, median（IQR）	70(39-97)	76(54-109)	0.100
Successful recanalization, n (%)	60(90.9)	72(88.9)	0.687
SICH, n (%)	2(3.0)	5(6.3)	0.605
Intraprocedural embolization, n (%)	2(3.0)	4(4.9)	0.871

Bold values indicate statistical significance.

§ 25 missing data; ‖ 5 missing data.

Abbreviations: IQR = interquartile range; DM = diabetes mellitus; WBC = white blood cell; NLR = neutrophil to lymphocyte ratio; IVT = intravenous thrombolysis; NIHSS = National Institute of Health Stroke Scale; ASPECTS = Alberta Stroke Program Early CT Score; ICAD = Intracranial atherosclerotic disease; IAT = intra-arterial thrombolysis; MT = mechanical thrombectomy; FPR = first pass recanalization; OTP = Onset-to-puncture time; SBP = systolic blood pressure; TOAST = Trial of ORG 10172 in Acute Stroke Treatment.